

Freedom of Information Act 2000 - Request Reference FoI/23/348

Urothelial and Colorectal Cancer

Information Requested:

1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?

- Avelumab
- Atezolizumab
- Carboplatin with Gemcitabine
- Carboplatin single or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin single or in any other combination
- Nivolumab
- Pembrolizumab
- Any other systemic anti-cancer therapy
- Palliative care only

2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?

- Aflibercept
- Bevacizumab
- Capecitabine
- CAPIRI
- CAPOX (XELOX)
- Cetuximab in combination with FOLFIRI/FOLFOX
- Cetuximab not in combination with FOLFIRI or FOLFOX
- Irinotecan only
- FOLFIRI
- FOLFOX
- Fluorouracil (5FU) only
- Oxaliplatin only
- Nivolumab
- Panitumumab in combination with FOLFIRI/FOLFOX
- Panitumumab not in combination with FOLFIRI or FOLFOX
- Pembrolizumab
- Raltitrexed
- Ramucirumab
- Regorafenib

- Tegafur + Uracil
- Any other systemic anti-cancer therapy
- Palliative care only

Response Details:

Cardiff and Vale University Health Board (the UHB) does not hold this information. Under Section 16 of the FOIA, which provides us with the duty to advise and assist, the UHB can inform you that Velindre NHS Trust may hold information relevant to your request and can be contacted via the following link:

FOI.VUNHST@wales.nhs.uk